Cerebral (Decline)

Cerebral, the telehealth mental health company, saw its valuation collapse and faced DEA investigation for ADHD medication prescribing practices. The company had grown rapidly during COVID by prescribing controlled substances via telemedicine, a practice regulators viewed increasingly skeptically. Like an organism that thrives on resources that become restricted, Cerebral's growth model faced existential regulatory risk.